PHIO

Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PHIO

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/29	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/21	06 : 03	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/21	05 : 59	Edgar (US Regulatory)	Form RW - Registration Withdrawal Request	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/18	05 : 45	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/17	22 : 04	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/17	22 : 04	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/17	22 : 00	GlobeNewswire Inc.	Phio Pharmaceuticals Secures New Investor	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/17	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/17	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/16	21 : 00	GlobeNewswire Inc.	Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/16	02 : 00	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/10	06 : 25	GlobeNewswire Inc.	Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/10	06 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/10	06 : 20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/09	06 : 04	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/09	06 : 02	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/05/09	06 : 00	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/04/30	20 : 30	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/04/23	02 : 10	GlobeNewswire Inc.	Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/04/16	20 : 30	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/04/11	20 : 30	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/04/03	20 : 30	GlobeNewswire Inc.	National Spotlight Features Phio’s Innovative RNAi Technology Platform	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/04/02	20 : 30	GlobeNewswire Inc.	Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/03/21	20 : 30	GlobeNewswire Inc.	Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/03/14	03 : 00	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/03/07	00 : 30	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/03/06	09 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/02/21	09 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/02/07	00 : 30	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:PHIO	Phio Pharmaceuticals Corporation
2024/01/31	22 : 00	GlobeNewswire Inc.	Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	NASDAQ:PHIO	Phio Pharmaceuticals Corporation